ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
9,412 announcements
Star Health reported a significant structural turnaround with underwriting profitability for the fifth consecutive quarter.
Q2FY27 revenue ₹7,518 Cr (+24% YoY), operating EBITDA ₹1,335 Cr (17.8% margin vs 23.2%), PAT ₹754 Cr (-14% YoY). Retail-led growth offsets US export disruption. FY27 EBITDA guidance reaffirmed.
Q2 FY27 revenue ₹11,797mn (+5.4% YoY), Adj. EBITDA ₹1,184mn (10.0% margin, -11.1% YoY), Adj. PAT ₹826mn (-17.8% YoY). Heltar AI acquisition adds conversational layer.
Q2FY27 standalone total income ₹228 Cr (+32.4%), H1 ₹430 Cr (+28.2%). Q2 PAT fell 31.2% on input-cost squeeze. Consolidated Q2 PAT ₹3 Cr.
H1 FY27 consolidated revenue ₹6,414Cr (+22%, 18% normalised), EBITDA ₹721Cr (+17%), PAT ₹364Cr (+9%); margins compressed, net cash ₹247Cr.
Q2 FY27 revenue Rs1,230Mn (+98% YoY), PAT Rs318Mn (+103%); H1 revenue Rs2,306Mn (+85%). Hobel consolidation from May 2026 drives growth.
H1 FY27 PAT ₹815 Cr (+57%); CISR improved to 97.9% from 100.3%; underwriting result ₹210 Cr vs loss ₹24 Cr. Retail fresh GWP +36%, driven by agency and D2C. Reported profit includes ₹229 Cr MTM gain.
Q2FY27 total income ₹827 Cr (+15.1%); EBITDA ₹131 Cr (+8.0%); PAT ₹75 Cr (-13.8%). Retail expansion via ZECODE/DEVO continues.
JSW Infrastructure (parent of Navkar) is pivotting to a logistics-heavy model while port margins suffer from the Fujairah disruption. Domestic growth remains strong, but international headwinds and capex execution are key monitorables.
Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
SAIL H1 FY27: turnover Rs 57,776 cr (+10.6%), EBITDA Rs 8,917 cr (15.4% margin), PAT Rs 3,410 cr (3x). Q2 PAT Rs 1,774 cr. Margin expansion driven by realisations.
Bajaj Auto delivered record revenue and EBITDA despite hyper-inflationary pressures, driven by export recovery and a surging EV portfolio. The 'True Narrative' shows a deliberate sacrifice of 100cc volumes to protect corporate margins.
Q2FY27 revenue ₹1,152 Cr (+15.8%), EBITDA ₹143 Cr (+10.0%), margin 12.4% (-66 bps), PAT ₹69 Cr (+9.7%). Record 10.0 Mn case volume; premiumisation and P&A-led strategy.
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Q2 FY27 consolidated revenue ₹3,044.61 Mn (+52.5% YoY), PAT ₹250.20 Mn (+21.2%), EBITDA margin 16.35% (down 285 bps) on input-cost headwinds. Capacity expansion underway.
SBI Life delivered a strong 19% growth in Value of New Business (VNB) and margin expansion, effectively managing a one-time ₹530 Cr GST impact while maintaining market leadership.
Q2 FY27 consolidated revenue ₹2,402.2 Mn (+44.2%), EBITDA ₹266.2 Mn (+58.5%), PAT ₹160.6 Mn (+102.1%), EBITDA margin 11.1%. Strategy: FIBC scale-up, Taslan yarn, non-wovens, UK/Italy expansion.
Q2 FY27: Revenue ₹1,912 cr (+33.1% YoY), Op. EBITDA ₹278 cr (+3.9%), PAT ₹77.6 cr (+3.0%). Volume-led growth; North (Nagaur) ramp-up; approved capacity to 43.3 MTPA grinding.
H1 FY27 revenue ₹42.20 Cr (+48.3% YoY), PAT ₹6.53 Cr (+45.9%), EBITDA margin 23.54%. Order book ₹77.42 Cr. No explicit forward guidance.
Q2 FY27 sales ₹933.9 Cr (+42.5%), PAT ₹13.7 Cr; H1 sales ₹2,968 Cr (+37.4%). Margins compressed on commodity costs; growth via capacity and backward integration.
Onesource Specialty Pharma delivered its third consecutive growth quarter, driven by new sterile cartridge capacity.
Q2 FY27 PAT ₹44 Cr (down 50% YoY) on total income ₹114 Cr; loan assets flat at ₹3,684 Cr; sanctions at an 8-year high.
Q2 FY27 revenue ₹13,517 Mn (+25.3% YoY), EBITDA ₹2,143 Mn (+20.8%), PAT ₹1,464 Mn (+17.1%). Debt-free, cash ₹14,474 Mn, ROCE 27%.
AWL delivered 26% revenue growth, but PAT dipped 2% due to local tax regulations in Bangladesh. Food and FMCG segment grew 32%, becoming a critical growth engine alongside stable edible oils.
JSW Infrastructure delivered healthy revenue growth of 18% YoY despite geopolitical disruptions in Fujairah.
WSFx delivered record Q2 turnover growth led by student remittances, despite macro headwinds in the US market. The pivot toward high-volume B2B channels is driving scale but compressing margins due to higher commission payouts.
Q2 FY27 revenue Rs 1,427 Cr (+38% YoY), EBITDA Rs 143 Cr (+28%), PAT Rs 102 Cr (+6%); H1 revenue Rs 2,902 Cr. Copper entry via RMIL acquisition.
Q2FY27 consolidated revenue Rs 12,767 Mn (+24%), EBITDA Rs 1,432 Mn (11.2% margin), PAT Rs 747 Mn (+4%). H1 revenue Rs 23,816 Mn (+19%). Strategy centres on value-added products and reduced EPC exposure.
Q2 FY27 revenue ₹2,037cr (+21.3% YoY), operating EBITDA ₹98cr (4.8% margin), reported PAT ₹56cr (+1% YoY). Store expansion continues; no explicit guidance given.